The primary aim of this study was to assess the prognostic significance of the CPS+EG score on disease-free survival (DFS) and overall survival (OS) in patients with HER2-positive breast cancer who received neoadjuvant therapy. The gene discussed is ERBB2; the disease is breast carcinoma.